<DOC>
	<DOCNO>NCT00330759</DOCNO>
	<brief_summary>The purpose study determine denosumab non-inferior zoledronic acid ( ZometaÂ® ) treatment bone metastasis ( lytic bone lesion multiple myeloma ) subject advanced cancer multiple myeloma ( exclude breast prostate cancer )</brief_summary>
	<brief_title>Study Denosumab vs. Zoledronic Acid Treat Bone Metastases Subjects With Advanced Cancer Multiple Myeloma .</brief_title>
	<detailed_description />
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Neoplasms , Second Primary</mesh_term>
	<mesh_term>Bone Neoplasms</mesh_term>
	<mesh_term>Bone Marrow Diseases</mesh_term>
	<mesh_term>Zoledronic acid</mesh_term>
	<mesh_term>Denosumab</mesh_term>
	<mesh_term>Diphosphonates</mesh_term>
	<criteria>Adults histologically/cystologically confirm advanced cancer include solid tumor , multiple myeloma , lymphoma Radiographic evidence least one bone metastasis ( lytic bone lesion multiple myeloma ) ; ECOG performance status 0 , 1 , 2 Adequate organ function Diagnosis breast prostate cancer Current prior intravenous bisphosphonate administration Current prior oral bisphosphonates bone metastasis , life expectancy le 6 month Prior history current evidence osteonecrosis/osteomyelitis jaw</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2014</verification_date>
	<keyword>Bone metastasis</keyword>
	<keyword>lytic bone lesion</keyword>
	<keyword>advanced cancer</keyword>
	<keyword>multiple myeloma</keyword>
	<keyword>lymphoma</keyword>
	<keyword>solid tumor</keyword>
	<keyword>skeletal related event</keyword>
	<keyword>skeletal fracture</keyword>
	<keyword>spinal cord compression , radiation bone</keyword>
	<keyword>surgery bone , bisphosphonates</keyword>
	<keyword>denosumab</keyword>
</DOC>